Want to see AKTS full AI Analyst Report?
AKTS Stock Chart & Stats
$25.99
--
Market closed
$25.99
--
Day’s Range― - ―
52-Week Range$14.72 - $34.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)272.99K
Market Cap
$1.45B
Enterprise Value$1.28K
Total Cash (Recent Filing)$517.32M
Total Debt (Recent Filing)$11.24M
Price to Earnings (P/E)―
Beta2.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,746,670
10 Day Avg. Volume325,281
30 Day Avg. Volume272,985
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.80Price Target Upside37.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ExpansionThe sharp revenue increase indicates meaningful early commercial traction and expanding product adoption. Sustaining this growth could improve operating leverage over time, although the company remains dependent on converting a small revenue base into recurring scale.
Strong Gross MarginStrong gross margin suggests the underlying offering may have attractive unit economics once development and operating costs normalize. This provides a potential foundation for future margin improvement if revenue scales and fixed costs are controlled.
Moderate Absolute DebtDebt remains modest in absolute dollars, which may limit direct interest and repayment pressure compared with a highly leveraged balance sheet. However, this benefit is constrained by negative equity and the company’s substantial funding requirements.
Bears Say
Severe UnprofitabilityThe scale of losses relative to revenue shows that the business is still far from breakeven. Continued operating deficits may require prolonged investment and make future profitability dependent on substantial revenue growth and cost discipline.
Heavy Cash BurnThe return to heavy operating and free cash flow burn indicates elevated funding needs and limited internal financial self-sufficiency. Persistent cash consumption increases execution risk and could constrain investment if external capital becomes less available.
Deteriorating Negative EquityDeepening negative equity weakens the capital structure and reduces financial flexibility. It raises reliance on equity issuance or other financing, creating meaningful dilution risk while also signaling that accumulated losses have materially eroded the balance sheet.
Aktis Oncology, Inc. News
AKTS FAQ
What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $1.45B.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aktis Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,746,670 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Currently, no hedge funds are holding shares in AKTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aktis Oncology, Inc. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
AKTS Stock 12 Month Forecast
Average Price Target
$35.80
▲(37.75% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Zymeworks
―
Oric Pharmaceuticals
―
Immunocore Holdings
―
Nanobiotix
―
Ownership Overview
47.33% Insiders
4.30% Mutual Funds
44.27% Other Institutional Investors
0.30% Public Companies and
Individual Investors